Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study-Reference-Cited by-同舟云学术

Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study

Published:2023-12 Issue: Volume:125 Page:111019
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Zang Mengya,Hu Xiaoyun,Yuan Guosheng,Li Rong,Li Wenli,Pang Huajin,Li Qi,Chen Jinzhang^ORCID

Funder

Guangdong Provincial Natural Science Foundation

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference30 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. Hepatocellular carcinoma;Llovet;Nat. Rev. Dis. Primers,2021

3. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma;Bruix;Gastroenterology,2016

4. Hepatocellular carcinoma;Forner;Lancet,2018

5. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current research status of transarterial therapies for hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

2. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma—A Retrospective Study;Annals of Surgical Oncology;2024-08-01